Skip to main content
SpringerLink
Log in

Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction

  • Hypertension and Emergency Medicine (T Rainer and P Levy, Section Editors)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In spite of advances in our understanding of acute heart failure (AHF) and its different phenotypic expressions, AHF management is still centered on volume removal with intravenous diuretics. This narrative review describes the pathophysiology underlying hypertensive AHF and appraises therapies targeting these mechanisms.

Recent Findings

Vascular redistribution rather than volume overload may be the primary determinant of elevated cardiac filling pressures and subsequent pulmonary congestion in patients with hypertensive AHF; in these patients, vasodilators should be the predominant treatment. Additional therapy with diuretics in hypertensive AHF should be relegated to the treatment of overt volume overload or persistent congestion in spite of optimized hemodynamics. Intravenous nitroglycerin at high doses can rapidly achieve pulmonary decongestion and reduce downstream critical care needs in these patients. The therapeutic role for synthetic peptides with vasodilator properties has yet to be defined.

Summary

Evidence supporting both old and new vasodilator therapies is limited by a paucity of well-designed studies and failure to demonstrate improvement in long-term outcomes. Targeted study of this phenotype of AHF is needed before vasodilator therapies become incorporated into treatment guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Viau DM, Sala-Mercado JA, Spranger MD, O'Leary DS, Levy PD. The pathophysiology of hypertensive acute heart failure. Heart. 2015;101(23):1861–7. https://doi.org/10.1136/heartjnl-2015-307461. This review explains the concepts of ventricular-vascular uncoupling, vascular redistribution and relfected aortic pulse waves in the context of hypertensive acute heart failure.

    Article  CAS  PubMed  Google Scholar 

  2. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16. https://doi.org/10.1016/j.ahj.2004.08.005.

    Article  PubMed  Google Scholar 

  3. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217–26. https://doi.org/10.1001/jama.296.18.2217.

    Article  CAS  PubMed  Google Scholar 

  4. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation. 1984;69(3):451–60. https://doi.org/10.1161/01.CIR.69.3.451.

    Article  CAS  PubMed  Google Scholar 

  5. Gelman S, Mushlin PS. Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology. 2004;100(2):434–9. https://doi.org/10.1097/00000542-200402000-00036.

    Article  PubMed  Google Scholar 

  6. MacIver DH, Clark AL. The vital role of the right ventricle in the pathogenesis of acute pulmonary edema. Am J Cardiol. 2015;115(7):992–1000. https://doi.org/10.1016/j.amjcard.2015.01.026.

    Article  PubMed  Google Scholar 

  7. Coiro S, Rossignol P, Ambrosio G, Carluccio E, Alunni G, Murrone A, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail. 2015;17(11):1172–81. https://doi.org/10.1002/ejhf.344.

    Article  PubMed  Google Scholar 

  8. Gargani L, Pang PS, Frassi F, Miglioranza MH, Dini FL, Landi P, et al. Persistent pulmonary congestion before discharge predicts rehospitalization in heart failure: a lung ultrasound study. Cardiovasc Ultrasound. 2015;13(1):40. https://doi.org/10.1186/s12947-015-0033-4.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.

    Article  PubMed  Google Scholar 

  10. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–77. https://doi.org/10.1016/j.jacc.2007.04.064.

    Article  PubMed  Google Scholar 

  11. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253–60. https://doi.org/10.1093/eurjhf/hfq133.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351(9100):389–93. https://doi.org/10.1016/S0140-6736(97)08417-1.

    Article  CAS  PubMed  Google Scholar 

  13. Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531–40.

    Google Scholar 

  14. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, et al. Tezosentan in patients with acute heart failure: design of the value of endothelin receptor inhibition with tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005;150(1):46–53. https://doi.org/10.1016/j.ahj.2005.04.035.

    Article  CAS  PubMed  Google Scholar 

  15. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. https://doi.org/10.1056/NEJMoa1100171.

    Article  PubMed  Google Scholar 

  16. Martindale JL, Secko M, Kilpatrick JF, de Souza IS, Paladino L, Aherne A, et al. Serial sonographic assessment of pulmonary edema in patients with hypertensive acute heart failure. J Ultrasound Med. 2017; https://doi.org/10.1002/jum.14336.

  17. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol. 2004;93(2):237–40. https://doi.org/10.1016/j.amjcard.2003.09.051.

    Article  CAS  PubMed  Google Scholar 

  18. Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, et al. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail. 1998;4(4):271–9. https://doi.org/10.1016/S1071-9164(98)90232-9.

    Article  CAS  PubMed  Google Scholar 

  19. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013;8:CD005151. https://doi.org/10.1002/14651858.CD005151.pub2.

    Google Scholar 

  20. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007;50(2):144–52. https://doi.org/10.1016/j.annemergmed.2007.02.022.

    Article  PubMed  Google Scholar 

  21. • Wilson SS, Kwiatkowski GM, Millis SR, Purakal JD, Mahajan AP, Levy PD. Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. Am J Emerg Med. 2017;35(1):126–31. https://doi.org/10.1016/j.ajem.2016.10.038. This retrospective cohort study shows that bolus-dose administration of intravenous nitroglycerin (compared with continuous infusion) is associated with reduced health resource utilization.

    Article  PubMed  Google Scholar 

  22. Nelson GI, Silke B, Ahuja RC, Hussain M, Taylor SH. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction. Lancet. 1983;1(8327):730–3.

    Article  CAS  PubMed  Google Scholar 

  23. Verma SP, Silke B, Hussain M, Nelson GI, Reynolds GW, Richmond A, et al. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol. 1987;10(1):38–46. https://doi.org/10.1097/00005344-198707000-00006.

    Article  CAS  PubMed  Google Scholar 

  24. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246–53. https://doi.org/10.1056/NEJM200007273430403.

    Article  CAS  PubMed  Google Scholar 

  25. Elsner D, Muders F, Muntze A, Kromer EP, Forssmann WG, Riegger GA. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J. 1995;129(4):766–73. https://doi.org/10.1016/0002-8703(95)90328-3.

    Article  CAS  PubMed  Google Scholar 

  26. Schmitt M, Gunaruwan P, Payne N, Taylor J, Lee L, Broadley AJ, et al. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol. 2004;24(5):911–7. https://doi.org/10.1161/01.ATV.zhq0504.7914.

    Article  CAS  PubMed  Google Scholar 

  27. Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376(20):1956–64. https://doi.org/10.1056/NEJMoa1601895.

    Article  CAS  PubMed  Google Scholar 

  28. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7(2):75–82. https://doi.org/10.1007/s11897-010-0010-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Nistri S, Bani D. Relaxin receptors and nitric oxide synthases: search for the missing link. Reprod Biol Endocrinol. 2003;1(1):5. https://doi.org/10.1186/1477-7827-1-5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res. 2003;92(1):32–40. https://doi.org/10.1161/01.RES.0000051884.27117.7E.

    Article  CAS  PubMed  Google Scholar 

  31. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39. https://doi.org/10.1016/S0140-6736(12)61855-8.

    Article  CAS  PubMed  Google Scholar 

  32. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678–84. https://doi.org/10.1056/NEJM199209033271002.

    Article  CAS  PubMed  Google Scholar 

  33. Tohmo H, Karanko M, Korpilahti K, Scheinin M, Viinamaki O, Neuvonen P. Enalaprilat in acute intractable heart failure after myocardial infarction: a prospective, consecutive sample, before-after trial. Crit Care Med. 1994;22(6):965–73. https://doi.org/10.1097/00003246-199406000-00015.

    Article  CAS  PubMed  Google Scholar 

  34. Hirschl MM, Binder M, Bur A, Herkner H, Brunner M, Mullner M, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med. 1995;155(20):2217–23. https://doi.org/10.1001/archinte.1995.00430200107014.

    Article  CAS  PubMed  Google Scholar 

  35. Annane D, Bellissant E, Pussard E, Asmar R, Lacombe F, Lanata E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation. 1996;94(6):1316–24. https://doi.org/10.1161/01.CIR.94.6.1316.

    Article  CAS  PubMed  Google Scholar 

  36. • Ayaz SI, Sharkey CM, Kwiatkowski GM, Wilson SS, John RS, Tolomello R, et al. Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department. Int J Emerg Med. 2016;9, 28(1) https://doi.org/10.1186/s12245-016-0125-4. The results of this retrospective cohort study demonstrated that bolus doses of enalaprilat in addition to standard therapy for hypertensive AHF effectively reduced blood pressure and were well tolerated.

Download references

Author information

Authors and Affiliations

  1. Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Sean Collins & Jennifer Martindale

Authors
  1. Sean Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Martindale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sean Collins.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and Emergency Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Collins, S., Martindale, J. Optimizing Hypertensive Acute Heart Failure Management with Afterload Reduction. Curr Hypertens Rep 20, 9 (2018). https://doi.org/10.1007/s11906-018-0809-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-018-0809-7

Keywords

Search

Navigation